Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-75.00M |
| EBITDA | $-1.07B |
| Operating Margin | 0.00% |
| Return on Equity | -30.50% |
| Return on Assets | -20.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $20.76 |
| Price-to-Book | 2.81 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $144.40M |
| Float | $132.21M |
| % Insiders | 0.50% |
| % Institutions | 114.62% |
Volatility is currently expanding
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
